CSI Market
Sign In | Register

Alzamend Neuro Inc (ALZN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ALZN quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Alzamend Neuro Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Apr 30 2026)
12 Months 		(Apr 30 2025) (Apr 30 2024) (Apr 30 2023) (Apr 30 2022)
Operating Activities
Income0.03
Depreciation & amortization0.11
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.71
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Interest Expense Debt Discount Related Party-
Increase Decrease In Prepaid Expenses Related Party-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.71
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.83
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-10.45
Discontinued operations0.00
Net Cash flow from Operating Activities-8.07
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Purchase Of Machinery-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.79
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock4.04
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Convertible Note Payable Related Party-
Proceeds From Note Receivable For Common Stock Related Party-
Proceeds From Convertible Note Payable-
Advances From Related Party Payable-
Proceeds From Shortterm Advances Related Party-
Cash And Cash Equivalents Period Increase Decrease-
Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs-
Proceeds From Issuance Of Preferred Stock Related Party-
Net Proceeds From Issuance Of Series Preferred Stock-
Net Proceeds From Issuance Of Series B Preferred Stock Related Party-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.83
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-8.07
Total Cash Flow-3.24
4 historic quarters locked

Sign in to unlock the full Alzamend Neuro Inc cash flow history.

Sign In Create Free Account

About Alzamend Neuro Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20260430)
  • Filed with the SEC: July 22, 2026
  • Source: az72426110k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001214659-26-008832

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License